Tagged with M

Generics Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did a US-based company look to establish itself in Taiwan, and then export back to the US? In my view, the US is not a very attractive environment for a company…

Biopharmaceuticals Over the past decade since its founding, what are some of the highlights in the transformation of Taiwan Advance Bio-Pharmaceutical Inc. (TABP) into a well established company? TABP was founded in 2000 as a spinoff of the Development Center for Biotechnology (DCB). The DCB was established in 1984 to support…

API Industry Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API industry decided to go global long before the formulation sector did. The reason is simple: the local market for APIs…

APAC Region PAREXEL has been in Asia Pacific (APAC) since the company entered Japan in 1995. It chose Taiwan as its regional base of operations with the 2007 acquisition of APEX, a company you founded in 1999. Today, does Taiwan continue to make sense as PAREXEL’s APAC headquarters? We believe that it…

Burrill & Company The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in Taiwan. During the six years that you have been with Burrill, you have mostly covered the Greater China region. What…

Mexico   Exactly 10 years ago Mexico realized that its public healthcare provision was inadequate as it was based on a system of employment benefits. This left over 50 million Mexicans without healthcare coverage because they were largely employed by the country’s widespread informal economy. The implementation of the Seguro Popular…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Dialysis The general manager of Baxter in the Nordic region discusses the concept of home care, and how brand new technologies currently being tested in Sweden should mean that soon, dialysis treatment will shift from the hospital to the home around the world. Could you please give us a brief introduction…

In-licensing An expert perspective on the possibilities of self-pay markets in Taiwan, and the opportunities afforded by bringing manufacturing of medical technology to the country, for export to the region. Uni-Pharma was founded in 1998, shortly after Taiwan introduced its national health insurance system. How was the business evolved over the…

Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…

Basic Research A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of biotech to drive the Taiwanese economy in the years to come, and Taiwan’s China connection. Participants:  Hsing-Jien Kung, President, National…

Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…